ArticleEBioMedicine2015
Rhinovirus-induced VP1-specific Antibodies are Group-specific and Associated With Severity of Respiratory Symptoms.
Article in EBioMedicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01159782 (Human Model of Rhinovirus Induced Acute Asthma Exacerbations), which is not on this map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Human Model of Rhinovirus Induced Acute Asthma Exacerbations
Who cites it
19 citing papers in PubMed, 27 citations in OpenAlex.
- PreDicta chip-based high resolution diagnosis of rhinovirus-induced wheeze.Nature communications · 2018Trial
- Risk factors for progression to bronchitis or pneumonia in hospitalized children with human rhinovirus infection: a retrospective cohort study using machine learning.Frontiers in pediatrics · 2026Article
- Clinical Significance of Rhinoviruses and Progress Toward Vaccination.Allergy, asthma & immunology research · 2025Review
- Association between asthma and IgG levels specific for rhinovirus and respiratory syncytial virus antigens in children and adults.The journal of allergy and clinical immunology. Global · 2025Article
- Rhinoviruses A and C elicit long-lasting antibody responses with limited cross-neutralization.Journal of medical virology · 2023Article
- Article
- Article
- Neutralization of SARS-CoV-2 requires antibodies against conformational receptor-binding domain epitopes.Allergy · 2022Article
- Article
- Enhanced Neutralizing Antibody Responses to Rhinovirus C and Age-Dependent Patterns of Infection.American journal of respiratory and critical care medicine · 2021Article
- Features of the Human Antibody Response against the Respiratory Syncytial Virus Surface Glycoprotein G.Vaccines · 2020Article
- ELISA-Based Assay for Studying Major and Minor Group Rhinovirus-Receptor Interactions.Vaccines · 2020Article
- Toward personalization of asthma treatment according to trigger factors.The Journal of allergy and clinical immunology · 2020Review
- MUW researcher of the month.Wiener klinische Wochenschrift · 2019Article
- Rhinovirus Species-Specific Antibodies Differentially Reflect Clinical Outcomes in Health and Asthma.American journal of respiratory and critical care medicine · 2018Article
- Mucosal Lining Fluid Biomarkers in Asthma: Basis for Rational Use of New Targeted Therapies?EBioMedicine · 2017Article
- Neonatal immune response to rhinovirus A16 has diminished dendritic cell function and increased B cell activation.PloS one · 2017Article
- Circulating Memory CD4+ T Cells Target Conserved Epitopes of Rhinovirus Capsid Proteins and Respond Rapidly to Experimental Infection in Humans.Journal of immunology (Baltimore, Md. : 1950) · 2016Article
- Developing Strategies to Treat Asthma Exacerbations Caused by Rhinovirus.EBioMedicine · 2015Article
Corrections and comments
- Commented on by
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRhinoviruses (RVs) are a major cause of common colds and induce exacerbations of asthma and chronic inflammatory lung diseases.
methodsWe expressed and purified recombinant RV coat proteins VP1-4, non-structural proteins as well as N-terminal fragments of VP1 from four RV strains (RV14, 16, 89, C) covering the three known RV groups (RV-A, RV-B and RV-C) and measured specific IgG-subclass-, IgA- and IgM-responses by ELISA in subjects with different severities of asthma or without asthma before and after experimental infection with RV16.
findingsBefore infection subjects showed IgG1 > IgA > IgM > IgG3 cross-reactivity with N-terminal fragments from the representative VP1 proteins of the three RV groups. Antibody levels were higher in the asthmatic group as compared to the non-asthmatic subjects. Six weeks after infection with RV16, IgG1 antibodies showed a group-specific increase towards the N-terminal VP1 fragment, but not towards other capsid and non-structural proteins, which was highest in subjects with severe upper and lower respiratory symptoms.
interpretationOur results demonstrate that increases of antibodies towards the VP1 N-terminus are group-specific and associated with severity of respiratory symptoms and suggest that it may be possible to develop serological tests for identifying causative RV groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.